Acrivon Therapeutics, Inc. (ACRV) earnings
ACRV earnings moved a median of -2.54% by the close. Quarterly and annual ACRV reports and results, each read against the price at its own news timestamp. Back to the ACRV overview →
19 measured ACRV earnings events.
Where these ACRV earnings landedvs 19 measured ACRV earnings reactions
| Middle 50% of ACRV earnings reactions | -8.36% to +1.46% |
|---|---|
| Median reaction (to close) | -2.54% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 ACRV earnings events with a measured close landed between -8.36% and +1.46%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts | Press release | -1.52% | +6.94% | |
| Form 10-Q Acrivon Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.52% | +6.94% | |
| Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts | Press release | +2.54% | -2.54% | |
| Form 10-Q Acrivon Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +2.54% | -2.54% | |
| Form 10-K Acrivon Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.63% | +7.59% | |
| Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | -3.65% | +1.46% | |
| Form 10-Q Acrivon Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.65% | +1.46% | |
| Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | Press release | -3.07% | -3.51% | |
| Form 10-Q Acrivon Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.07% | -3.51% | |
| Form 10-K Acrivon Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -6.65% | -9.68% | |
| Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | Press release | -2.46% | -7.03% | |
| Form 10-Q Acrivon Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.46% | -7.03% | |
| Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | Press release | — | -11.15% | |
| Form 10-Q Acrivon Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | -11.15% | |
| Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | Press release | -0.48% | +0.48% | |
| Form 10-Q Acrivon Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.48% | +0.48% | |
| Form 10-K Acrivon Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.45% | +13.67% | |
| Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights | Press release | +0.00% | -15.93% | |
| Form 10-Q Acrivon Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -15.93% |
Keep exploring
More ACRV: analyst actions → · SEC filings → · ACRV overview →